Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2025-04-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about changes in accounting policies based on new accounting standards issued by the Ministry of Finance of China. It explains the reasons for the changes, the dates of the new standards, the previous and new accounting policies, and states that the changes will not have a significant impact on the company's financials. The document is relatively short (1485 characters) and does not contain any financial statements or detailed financial data. It is a regulatory announcement about accounting policy changes rather than a full financial report or audit report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-04-27 Chinese
独立董事述职报告 （雷新途）
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度独立董事述职报告" which translates to "2024 Annual Independent Director's Work Report." It details the independent director's duties, attendance at board and committee meetings, communication with auditors, and oversight activities during the 2024 fiscal year. The content focuses on the independent director's report on their work and responsibilities rather than the full annual report or financial statements. It is a specialized report by an independent director about their role and activities, which fits the category of Board/Management Information (MANG) as it relates to management and board-level disclosures. The document length is about 4808 characters, which is substantial and contains detailed narrative rather than a brief announcement or certification. Therefore, it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA). It is not an audit report or financial report but a management-level report on director duties and governance.
2025-04-27 Chinese
年度关联方资金占用专项审计报告
Audit Report / Information Classification · 95% confidence The document is a specialized report titled "亿帆医药股份有限公司 非经营性资金占用及其他关联资金往来情况的专项报告" which translates to a special report on non-operating fund occupation and other related party fund transactions for the year 2024. It includes detailed financial data tables about fund balances, transactions, and interest related to non-operating funds and related party transactions. The report is prepared in accordance with regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange self-regulatory guidelines. It is signed by certified public accountants and approved by the board on April 24, 2025. The document is not a full annual report or interim report but a standalone audit-related special report focusing on specific financial and regulatory compliance matters. It contains substantive financial data and audit confirmations but is not a general financial statement report like a 10-K or IR. It is not an announcement or certification only, but a detailed audit report on a specific topic. Therefore, it fits best under the category Audit Report / Information (AR). FY 2024
2025-04-27 Chinese
关于对2024年度会计师事务所履职情况的评估报告
Audit Report / Information Classification · 95% confidence The document is an evaluation report on the performance of the accounting firm (立信会计师事务所) for the 2024 annual audit of 亿帆医药股份有限公司. It discusses the qualifications, audit process, quality control, and risk management of the auditor during the 2024 annual audit. The document does not contain actual financial statements or detailed financial results but rather assesses the auditor's work and compliance with regulations. It is not the annual report itself but an audit-related evaluation report. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and assessments related to audit processes, excluding full annual reports. The document length is under 5,000 characters, but it is a substantive evaluation report, not a mere announcement or certification letter, so it is not RPA or RNS. Therefore, the correct classification is AR with high confidence. FY 2024
2025-04-27 Chinese
2024年年度报告
Annual Report Classification · 100% confidence The document is titled '2024 年年度报告全文' which translates to '2024 Annual Report Full Text'. It includes detailed sections such as company overview, financial data, management discussion and analysis, governance, environmental and social responsibility, and financial statements. The document contains comprehensive financial figures, management commentary, risk disclosures, and audit information. The presence of detailed financial data and management analysis confirms it is a full annual report rather than a summary or announcement. The document length is substantial (15,000 characters), indicating it is the full report, not just an announcement of the report. Therefore, the document fits the definition of an Annual Report (10-K). FY 2024
2025-04-27 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the supervisory board (监事会) of 亿帆医药股份有限公司 regarding their 13th meeting of the 8th supervisory board. It includes approvals of various reports such as the 2024 supervisory board work report, the 2024 annual report and its summary, profit distribution plan, internal control self-evaluation report, audit firm appointment, and other related matters. The document is a formal announcement of meeting resolutions and approvals rather than the full reports themselves. It also references that the detailed 2024 supervisory board work report is disclosed elsewhere (on a website). The document length is short (1449 characters) and mainly serves as an official announcement of meeting decisions and approvals. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice, not as the full Annual Report (10-K) or Audit Report (AR).
2025-04-27 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.